Editorial note: Heally providers prescribe both semaglutide and tirzepatide, so we have a stake in this topic. We base this comparison on FDA labels and published clinical trials, linked in the sources below. The choice of medication is made by you and your provider, based on your health history.
Tirzepatide and semaglutide are the two leading GLP-1 medications for weight loss and type 2 diabetes. Semaglutide is sold as Ozempic, Wegovy and Rybelsus, and the Wegovy pill. Tirzepatide is sold as Mounjaro and Zepbound. They are often discussed together and prescribed for similar conditions. Still, they are different drugs, with different mechanisms, dosing schedules, results, approvals and ideal candidates.
This guide compares tirzepatide and semaglutide dosage, weight loss, side effects and cost, using the latest trial data and FDA labels as of October 2026. You can use it to prepare for a conversation with your provider.
Key takeaways
- Tirzepatide is a once-weekly injection. Semaglutide comes as a once-weekly injection (Ozempic, Wegovy) or a daily pill (Rybelsus, Wegovy pill)
- Tirzepatide is a dual GLP-1 and GIP receptor agonist. Semaglutide is a GLP-1 receptor agonist only. This is the core mechanistic difference
- In the SURMOUNT-5 head-to-head trial (NEJM 2025), tirzepatide led to 20.2% average weight loss vs 13.7% with semaglutide over 72 weeks
- Tirzepatide dosing starts at 2.5 mg and goes up to 15 mg weekly. Wegovy starts at 0.25 mg and goes up to 2.4 mg, or 7.2 mg with Wegovy HD
- Side effect profiles are broadly similar, and both carry the same FDA boxed warning for thyroid C-cell tumors
- Both now have proven cardiovascular data. Wegovy’s comes from the SELECT trial, and Mounjaro’s from SURPASS-CVOT (FDA approval in August 2026)
- The right choice depends on your goals, health history, insurance and individual response, not just average results
- Talk to a Heally licensed provider about which medication fits you
The core difference between semaglutide and tirzepatide: how each drug works
The most important difference between tirzepatide and semaglutide is their mechanism of action, meaning which hormone receptors they activate.
Semaglutide
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a gut hormone released after eating. It signals the brain to reduce appetite and slows stomach emptying, so you feel full longer. It also boosts insulin release and lowers glucagon, which would otherwise raise blood sugar. Semaglutide mimics this hormone but lasts much longer, so once-weekly dosing works.
Considering semaglutide? Compare Wegovy injections and Wegovy pills. A Heally provider will review your health history and prescribe only if it’s right for you.
Tirzepatide
Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, sometimes called a “twincretin.” GIP is a second gut hormone involved in insulin release, fat storage and energy use. By activating both receptors, tirzepatide has broader metabolic effects than GLP-1 activation alone. Research suggests GIP action in fat tissue may also help explain tirzepatide’s larger weight loss in trials, though scientists are still studying exactly how.
Considering tirzepatide? Learn about Zepbound or start with Heally’s tirzepatide program. Your provider will check whether it’s a safe fit before prescribing.
Mechanism edge: tirzepatide. Tirzepatide’s dual GLP-1 and GIP action creates broader metabolic effects. Still, both mechanisms are clinically proven. Semaglutide’s GLP-1-only approach produces substantial, well-documented weight loss and blood sugar control on its own. For a plain-language explainer of the two drugs, see tirzepatide vs semaglutide: what’s the difference.
FDA approvals: what each drug is officially indicated for
| Indication | Semaglutide | Tirzepatide |
|---|---|---|
| Type 2 diabetes | Ozempic (injection), Rybelsus (pill) | Mounjaro |
| Chronic weight management | Wegovy injection, Wegovy HD and Wegovy pill | Zepbound |
| Cardiovascular risk reduction | Wegovy (adults with obesity and heart disease), Ozempic (type 2 diabetes) | Mounjaro (adults with type 2 diabetes at high cardiovascular risk, approved 2026) |
| Obstructive sleep apnea (OSA) | Not approved | Zepbound (approved 2024) |
| MASH (liver disease with fibrosis) | Wegovy 2.4 mg (accelerated approval, 2025) | Not approved |
| Adolescents with obesity (12 to 17) | Wegovy | Not approved under 18 |
| Children with type 2 diabetes (10 to 17) | Not approved for Ozempic | Mounjaro (ages 10 and older) |
| Oral form | Rybelsus (type 2 diabetes), Wegovy pill (weight loss) | Injection only |
Sources: FDA prescribing information for Wegovy, Mounjaro and Zepbound; FDA Wegovy label 2025; FDA Mounjaro label 2026
Approval breadth edge: semaglutide. Semaglutide holds more FDA indications, including weight-related heart protection, adolescent use, liver disease (MASH) and two oral forms. Tirzepatide is catching up. It added sleep apnea in 2024 and cardiovascular risk reduction for type 2 diabetes in 2026.
Semaglutide and tirzepatide efficacy in weight loss comparison
This is where the two drugs diverge most clearly, and where the strongest clinical evidence now exists.
| Drug | Trial | Duration | Dose | Average weight loss |
|---|---|---|---|---|
| Tirzepatide | SURMOUNT-5 (head-to-head) | 72 weeks | Max tolerated, 10 or 15 mg | 20.2% |
| Semaglutide | SURMOUNT-5 (head-to-head) | 72 weeks | Max tolerated, 1.7 or 2.4 mg | 13.7% |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 15 mg | 20.9% |
| Semaglutide | STEP 1 | 68 weeks | 2.4 mg | 14.9% |
| Semaglutide | STEP UP | 72 weeks | 7.2 mg (Wegovy HD) | About 19% to 21% |
SURMOUNT-1 and STEP 1 were separate placebo-controlled trials, so compare them with caution. Only SURMOUNT-5 tested the two drugs directly against each other.
The SURMOUNT-5 trial was published in the New England Journal of Medicine in May 2025. It was the first randomized, head-to-head comparison of the two medications in adults with obesity but without type 2 diabetes. It enrolled 751 adults and ran for 72 weeks, with each drug at its maximum tolerated dose. Tirzepatide led to 20.2% average weight loss, compared with 13.7% for semaglutide. That’s a statistically significant 6.5 percentage point difference. People on tirzepatide were also more likely to reach 10%, 15%, 20% and 25% weight loss.
A 2025 meta-analysis of many studies confirmed tirzepatide’s advantage. It found about 4 percentage points more weight loss with tirzepatide on average, and the gap grew with higher doses and longer treatment. Real-world data point the same way. In a 2024 JAMA Internal Medicine study of more than 18,000 US adults, tirzepatide users lost about 15.3% of their body weight at 12 months, compared with 8.3% for semaglutide users.
One 2026 update narrows the gap. Wegovy HD (semaglutide 7.2 mg) was approved in March 2026 for people who have tolerated 2.4 mg for at least 4 weeks and need more weight loss. In the STEP UP trial, its results came close to tirzepatide’s.
Weight loss edge: tirzepatide. Tirzepatide produces greater average weight loss than standard-dose semaglutide in head-to-head trials and real-world data. That said, semaglutide still produces meaningful, life-improving weight loss for most people who take it. For month-by-month expectations, see how much weight you can lose on Mounjaro in a month.
Semaglutide and tirzepatide efficacy in blood sugar control for type 2 diabetes
Both medications significantly lower HbA1c, the key long-term blood sugar marker. Tirzepatide again shows stronger results in head-to-head comparisons.
| Metric | Tirzepatide | Semaglutide |
|---|---|---|
| HbA1c reduction (top doses, trials) | -2.0% to -2.4% | -1.6% to -1.9% |
| HbA1c reduction (real-world, 12 months) | -1.3% (GLP-1 naive patients) | -0.9% (GLP-1 naive patients) |
| Weight lost (real-world, type 2 diabetes, 12 months) | -10.2 kg | -6.1 kg |
| SURPASS-2 vs semaglutide 1 mg (HbA1c) | -2.0% to -2.3% (all tirzepatide doses) | -1.86% |
| Cardiovascular outcomes trial | SURPASS-CVOT: 8% fewer major events vs dulaglutide (not statistically superior) | SELECT: 20% fewer major events vs placebo |
Sources: Real-world HbA1c study, PMC 2025; SURPASS-2, NEJM 2021; SURPASS-CVOT approval, Pharmacy Times 2026
Heart protection is an important difference to understand. The SELECT trial (2023) showed that Wegovy lowered the risk of major adverse cardiovascular events (MACE), such as heart attack, stroke and cardiovascular death, by 20% compared with placebo. It included people with obesity and established heart disease, without diabetes.
Tirzepatide’s SURPASS-CVOT trial reported in 2025. It compared tirzepatide with dulaglutide, another GLP-1 drug with proven heart benefits, in 13,299 adults with type 2 diabetes and heart disease. Tirzepatide had 8% fewer major events. That met the goal of being at least as good as dulaglutide, but was not statistically better. In August 2026, the FDA approved Mounjaro to lower cardiovascular risk in adults with type 2 diabetes at high risk.
For people with heart disease and obesity but no diabetes, semaglutide still has the more direct evidence. Talk this through with your provider if you have a history of heart attack or stroke.
2026 update. In August 2025, the FDA granted accelerated approval to Wegovy 2.4 mg for MASH (formerly NASH) with moderate to advanced liver fibrosis. In December 2025, the Wegovy pill became the first oral GLP-1 approved for weight loss. In March 2026, Wegovy HD (7.2 mg) was approved for additional weight loss. For tirzepatide, Zepbound was approved for obstructive sleep apnea in adults with obesity in December 2024. It was the first medication approved for OSA. Mounjaro added a cardiovascular indication in August 2026.
Semaglutide and tirzepatide dosing comparison
Dosing is one of the most practical differences between tirzepatide and semaglutide. The numbers aren’t comparable milligram for milligram. A 2.4 mg dose of semaglutide is not “weaker” than 15 mg of tirzepatide just because the number is smaller, since they are different molecules.
| Dosing feature | Semaglutide | Tirzepatide |
|---|---|---|
| Starting dose | 0.25 mg weekly (Ozempic, Wegovy); 1.5 mg daily (Wegovy pill); 3 mg daily (Rybelsus) | 2.5 mg weekly |
| Titration interval | Every 4 weeks | Every 4 weeks, in 2.5 mg steps |
| Maintenance doses | Ozempic 0.5, 1 or 2 mg; Wegovy 1.7 or 2.4 mg; Wegovy pill 25 mg daily | 5, 10 or 15 mg weekly (Zepbound); up to 15 mg (Mounjaro) |
| Maximum dose | 7.2 mg weekly (Wegovy HD); 2 mg weekly (Ozempic) | 15 mg weekly |
| Time to reach top standard dose | 16 weeks to 2.4 mg (Wegovy) | 20 weeks to 15 mg |
| How it’s taken | Injection or daily pill | Injection only |
| Devices | Wegovy single-dose pen; Ozempic multi-dose pen; tablets | Zepbound single-dose pen, KwikPen and vials; Mounjaro single-dose pen |
| Half-life | About 7 days | About 5 days |
| Missed dose window | Wegovy: take within 5 days; Ozempic: within 5 days | Within 4 days |
Tirzepatide dosing schedule
| Weeks | Tirzepatide dose |
|---|---|
| 1 to 4 | 2.5 mg (starter dose) |
| 5 to 8 | 5 mg |
| 9 to 12 | 7.5 mg |
| 13 to 16 | 10 mg |
| 17 to 20 | 12.5 mg |
| 21 onward | 15 mg (if needed) |
Wegovy (semaglutide) dosing schedule
| Weeks | Wegovy dose |
|---|---|
| 1 to 4 | 0.25 mg |
| 5 to 8 | 0.5 mg |
| 9 to 12 | 1 mg |
| 13 to 16 | 1.7 mg |
| 17 onward | 2.4 mg (maintenance), or 1.7 mg if 2.4 mg isn’t tolerated |
| After at least 4 weeks on 2.4 mg | 7.2 mg (Wegovy HD), if your provider recommends more weight loss |
You don’t have to reach the top dose on either drug. Many people stay on a lower dose that works well for them. Your provider may also keep you at a dose longer if side effects are hard to manage. For timing rules, see how long to stay on each GLP-1 dose before increasing, our full tirzepatide dosing guide and what to know about the highest dose of Mounjaro.
Is there an equivalent dose between tirzepatide and semaglutide?
There is no official conversion. When people switch, providers usually look at the current dose, how well it’s working and side effects. For example, someone on Wegovy 2.4 mg who switches to tirzepatide often starts at 2.5 mg or 5 mg, depending on the provider’s judgment. Never switch on your own. See how to switch from Zepbound to Wegovy for what the process looks like.
Comparing pills and shots? Read our Wegovy pills vs injection guide · Learn about Foundayo, another daily GLP-1 pill · Check your baseline with a weight loss lab panel
Semaglutide and tirzepatide side effects: how do they compare?
Because both drugs activate the GLP-1 pathway, their side effects are very similar. The differences are of degree, not kind.
Common side effects shared by both medications:
- Nausea, the most common, which usually peaks during dose increases and then eases
- Vomiting
- Diarrhea or constipation
- Decreased appetite and early fullness
- Bloating or stomach discomfort
- Injection site reactions (injections only)
Key safety warnings that apply to both drugs:
- FDA boxed warning: possible risk of thyroid C-cell tumors, based on animal studies. Neither drug should be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pancreatitis: both carry a warning. Stop the medication and get care if it’s suspected
- Gallbladder disease: both raise the risk of gallstones and gallbladder inflammation, especially with rapid weight loss
- Low blood sugar: mainly in people with type 2 diabetes who also take insulin or a sulfonylurea
- Kidney problems: severe vomiting or diarrhea can cause dehydration and acute kidney injury
- Birth control pills (tirzepatide only): tirzepatide can make birth control pills less effective. Lilly advises a backup method for 4 weeks after starting and after each dose increase
Where do they differ in side effects?
In most comparisons, overall rates of digestive side effects are similar. Some meta-analyses found slightly higher rates of serious adverse events at higher tirzepatide doses (10 to 15 mg) than with semaglutide. However, results vary between studies, and the absolute differences are small. Appetite suppression can also feel stronger on tirzepatide. Some people welcome that, while others find it uncomfortable.
Side effect tolerability edge: semaglutide (slight). Both drugs have similar side effect profiles overall. Semaglutide has a slightly better serious adverse event rate in some comparative data. It also has a longer real-world safety track record, with Wegovy approved for weight loss since 2021 and Ozempic since 2017. For a deeper look, see which has fewer side effects, semaglutide or tirzepatide and our guide to tirzepatide side effects.
Semaglutide and tirzepatide difference in cost and insurance in 2026
Cost is often the deciding factor. Brand-name versions of both medications are expensive at list price, but self-pay options have changed the picture in 2026.
| Cost factor | Semaglutide | Tirzepatide |
|---|---|---|
| Brand-name list price per month | About $1,000 to $1,350 (Ozempic, Wegovy) | About $1,050 to $1,100 (Mounjaro, Zepbound) |
| Manufacturer self-pay price | Wegovy pens 349/month(199 for the first 2 fills through 12/31/2026); Wegovy HD $399; Wegovy pill $149 to $299 | Zepbound through LillyDirect from $299/month |
| Savings card with commercial insurance | Wegovy savings offer (as low as $25, with a monthly cap) | Zepbound savings card |
| Medicare | GLP-1 Bridge program: $50/month for Wegovy (7/1/2026 to 12/31/2027) | GLP-1 Bridge program: $50/month for Zepbound |
| Insurance coverage for obesity | Varies by plan; Wegovy has a longer formulary history | Varies by plan; Zepbound coverage is growing |
| Cost per 1% of body weight lost (list price) | About $1,845 | About $985 |
Prices as of October 2026 and subject to change. Confirm current pricing with your pharmacy, insurer or the manufacturer. Cost-per-outcome figures are based on list prices. Source: Drugs.com comparison
At list prices, tirzepatide’s greater weight loss makes it nearly 2 times more cost-efficient per unit of outcome. Source: Drugs.com.
Measured as cost per percentage point of body weight lost, tirzepatide is more cost-efficient at brand-name prices. Its list price is similar, but it produces more weight loss per dollar. Your actual cost depends on your insurance, savings programs and which version you use.
A note on compounded GLP-1s. The FDA removed tirzepatide from its drug shortage list in December 2024 and semaglutide in February 2025. Since then, pharmacies can no longer mass-produce copies of these drugs. Compounded versions are not FDA approved, and the FDA has received reports of dosing errors and hospitalizations linked to them. If you’re considering a compounded option, ask your provider why it’s medically necessary for you and which pharmacy makes it.
For more on pricing, see what you’ll pay for Wegovy with no insurance and how to use the Zepbound savings card.
Who should choose tirzepatide?
Tirzepatide may be a better fit for:
- People whose main goal is maximum weight loss, and who want the drug with the strongest head-to-head data
- People who have plateaued on semaglutide and need a more potent option
- Adults with obesity and obstructive sleep apnea, since Zepbound is approved for OSA
- People with type 2 diabetes who need a stronger HbA1c reduction
- People with type 2 diabetes and high cardiovascular risk, now that Mounjaro has a cardiovascular indication
- People whose insurance or self-pay price makes tirzepatide comparable to or cheaper than semaglutide
Who should choose semaglutide?
Semaglutide may be a better fit for:
- People with obesity and established heart disease but no diabetes, who benefit from the SELECT trial’s proven reduction in heart attack and stroke
- Teens aged 12 to 17 with obesity, since Wegovy is approved for this age group and tirzepatide is not
- People who prefer a pill, such as the Wegovy pill for weight loss or Rybelsus for type 2 diabetes
- People with MASH and liver fibrosis, since Wegovy 2.4 mg is approved for this condition
- People for whom semaglutide is more affordable or better covered by insurance
- First-time GLP-1 users who want the medication with the longest real-world safety track record
The bottom line
Tirzepatide and semaglutide both lead to significant weight loss and better blood sugar control. In the SURMOUNT-5 head-to-head trial, tirzepatide led to more weight loss: 20.2% vs 13.7% over 72 weeks. Tirzepatide is dosed from 2.5 mg to 15 mg weekly, while Wegovy goes from 0.25 mg to 2.4 mg, or 7.2 mg with Wegovy HD. Semaglutide offers more FDA approvals, pill options and the most direct heart-protection evidence for people without diabetes. Side effects are similar for both. Cost depends heavily on your insurance and self-pay options. The best choice depends on your goals, health history and budget, and it’s a decision to make with a licensed provider.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
In terms of average weight loss and blood sugar reduction, yes. In the SURMOUNT-5 head-to-head trial, tirzepatide led to about 20% weight loss vs about 14% with semaglutide over 72 weeks. However, “stronger” doesn’t mean right for everyone. Individual responses vary, and semaglutide produces meaningful results for most people who take it.
What is the tirzepatide dose equivalent to semaglutide?
There is no official dose conversion. The two drugs are different molecules, so milligrams can’t be compared directly. When switching, providers choose a starting dose based on your current dose, results and side effects.
Can I take tirzepatide and semaglutide together?
No. These medications should not be taken at the same time. Both act on GLP-1 receptors, so combining them raises the risk of severe digestive side effects and low blood sugar, with no proven extra benefit. If you switch, your provider will usually have you start the new medication when your next dose of the old one would be due.
Which is better for weight loss: Ozempic or Mounjaro?
Mounjaro (tirzepatide) produces more weight loss on average than Ozempic (semaglutide) in clinical trials. However, both are approved for type 2 diabetes, not weight loss. Wegovy and Zepbound are the weight loss versions, so for obesity the relevant comparison is Zepbound vs Wegovy. See our pages on Ozempic and Mounjaro for details.
Which drug has fewer side effects?
Both have similar side effect profiles, mostly digestive symptoms such as nausea, vomiting, diarrhea and constipation. Some data show slightly higher rates of serious adverse events with high-dose tirzepatide (10 to 15 mg). If you had intolerable side effects on one medication, switching to the other under medical supervision may help.
Does semaglutide have better cardiovascular benefits than tirzepatide?
For people with obesity and heart disease but no diabetes, semaglutide has the stronger evidence. The SELECT trial showed a 20% reduction in heart attack, stroke and cardiovascular death. For people with type 2 diabetes, tirzepatide’s SURPASS-CVOT trial showed results at least as good as dulaglutide, and Mounjaro was approved to reduce cardiovascular risk in August 2026.
Which is more cost-effective?
At list prices, tirzepatide is more cost-efficient per percentage point of weight lost: about $985 vs $1,845 per 1%. In 2026, manufacturer self-pay prices start at $299 a month for Zepbound and $349 a month for Wegovy pens. Your actual cost depends on your insurance and savings programs.
Is there a generic version of tirzepatide or semaglutide?
No. As of October 2026, there are no FDA-approved generics of tirzepatide or semaglutide in the US. Both are still under patent protection. Generic liraglutide, an older daily GLP-1, has been available since 2024. Compounded versions are not FDA approved, and mass compounding ended after the drug shortages were resolved in 2024 and 2025.
Sources
- Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity” (SURMOUNT-5). New England Journal of Medicine, 2025. nejm.org
- Rodriguez PJ, et al. “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.” JAMA Internal Medicine, 2024. jamanetwork.com
- Meta-analysis: comparative efficacy of tirzepatide vs semaglutide. PMC, 2025. pmc.ncbi.nlm.nih.gov
- Real-world HbA1c and weight outcomes: tirzepatide vs semaglutide in type 2 diabetes. PMC, 2025. pmc.ncbi.nlm.nih.gov
- Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes” (SURPASS-2). New England Journal of Medicine, 2021. nejm.org
- Pharmacy Times. “FDA approves tirzepatide to cut CV risk in type 2 diabetes,” August 2026. pharmacytimes.com
- HCPLive. “FDA approves higher-dose semaglutide (Wegovy HD) injection 7.2 mg for obesity,” March 2026. hcplive.com
- HCPLive. “FDA approves semaglutide (Wegovy) injection 2.4 mg for noncirrhotic MASH,” August 2025. hcplive.com
- US Food and Drug Administration. “FDA’s concerns with unapproved GLP-1 drugs used for weight loss.” fda.gov
- US Food and Drug Administration. Prescribing information for Wegovy, Ozempic, Zepbound and Mounjaro.
Medical disclaimer
This article is for informational and educational purposes only. It does not replace medical advice, diagnosis or treatment. It reflects publicly available clinical data and FDA labels as of October 2026. Clinical trial results are averages, and individual responses vary. Semaglutide and tirzepatide are prescription medications that require evaluation by a licensed healthcare provider. Do not start, stop or change any medication without talking to your doctor. Heally connects patients with independent licensed healthcare providers. Heally itself does not prescribe medications or provide medical advice. All prices are approximate and may change, so check costs with your pharmacy and insurance plan. Both medications carry an FDA boxed warning about the risk of thyroid C-cell tumors.
